132 related articles for article (PubMed ID: 24677033)
1. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Reid ME; El Beshlawy A; Inati A; Kutlar A; Abboud MR; Haynes J; Ward R; Sharon B; Taher AT; Smith W; Manwani D; Ghalie RG
Am J Hematol; 2014 Jul; 89(7):709-13. PubMed ID: 24677033
[TBL] [Abstract][Full Text] [Related]
2. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Kutlar A; Reid ME; Inati A; Taher AT; Abboud MR; El-Beshlawy A; Buchanan GR; Smith H; Ataga KI; Perrine SP; Ghalie RG
Am J Hematol; 2013 Nov; 88(11):E255-60. PubMed ID: 23828223
[TBL] [Abstract][Full Text] [Related]
3. A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.
Kutlar A; Ataga K; Reid M; Vichinsky EP; Neumayr L; Blair-Britt L; Labotka R; Glass J; Keefer JR; Wargin WA; Berenson R; Perrine SP
Am J Hematol; 2012 Nov; 87(11):1017-21. PubMed ID: 22887019
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.
Fucharoen S; Inati A; Siritanaratku N; Thein SL; Wargin WC; Koussa S; Taher A; Chaneim N; Boosalis M; Berenson R; Perrine SP
Br J Haematol; 2013 May; 161(4):587-93. PubMed ID: 23530969
[TBL] [Abstract][Full Text] [Related]
5. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
Perrine SP; Ginder GD; Faller DV; Dover GH; Ikuta T; Witkowska HE; Cai SP; Vichinsky EP; Olivieri NF
N Engl J Med; 1993 Jan; 328(2):81-6. PubMed ID: 7677966
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.
Perrine SP; Wargin WA; Boosalis MS; Wallis WJ; Case S; Keefer JR; Faller DV; Welch WC; Berenson RJ
J Clin Pharmacol; 2011 Aug; 51(8):1186-94. PubMed ID: 21422239
[TBL] [Abstract][Full Text] [Related]
7. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
Ataga KI; Reid M; Ballas SK; Yasin Z; Bigelow C; James LS; Smith WR; Galacteros F; Kutlar A; Hull JH; Stocker JW;
Br J Haematol; 2011 Apr; 153(1):92-104. PubMed ID: 21323872
[TBL] [Abstract][Full Text] [Related]
8. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.
Atweh GF; Sutton M; Nassif I; Boosalis V; Dover GJ; Wallenstein S; Wright E; McMahon L; Stamatoyannopoulos G; Faller DV; Perrine SP
Blood; 1999 Mar; 93(6):1790-7. PubMed ID: 10068649
[TBL] [Abstract][Full Text] [Related]
9. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y; Miller ST; Kanter J; Lanzkron S; Smith WR; Hsu LL; Gordeuk VR; Viswanathan K; Sarnaik S; Osunkwo I; Guillaume E; Sadanandan S; Sieger L; Lasky JL; Panosyan EH; Blake OA; New TN; Bellevue R; Tran LT; Razon RL; Stark CW; Neumayr LD; Vichinsky EP;
N Engl J Med; 2018 Jul; 379(3):226-235. PubMed ID: 30021096
[TBL] [Abstract][Full Text] [Related]
10. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies.
Sher GD; Ginder GD; Little J; Yang S; Dover GJ; Olivieri NF
N Engl J Med; 1995 Jun; 332(24):1606-10. PubMed ID: 7753139
[TBL] [Abstract][Full Text] [Related]
11. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
[TBL] [Abstract][Full Text] [Related]
12. Intrapatient variability in fetal hemoglobin measurements over time in sickle cell patients not on fetal hemoglobin inducing agents.
Knapp E; Cohen H; Kutlar A; Ghalie R; Manwani D
Am J Hematol; 2016 Mar; 91(3):E11-2. PubMed ID: 26661045
[No Abstract] [Full Text] [Related]
13. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
[TBL] [Abstract][Full Text] [Related]
14. Haemoglobin F modulation in childhood sickle cell disease.
Trompeter S; Roberts I
Br J Haematol; 2009 Feb; 144(3):308-16. PubMed ID: 19036119
[TBL] [Abstract][Full Text] [Related]
15. Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders.
Perrine SP; Olivieri NF; Faller DV; Vichinsky EP; Dover GJ; Ginder GD
Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):67-71. PubMed ID: 7508690
[TBL] [Abstract][Full Text] [Related]
16. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.
Al-Nood HA; Al-Khawlani MM; Al-Akwa A
Hemoglobin; 2011; 35(1):13-21. PubMed ID: 21250877
[TBL] [Abstract][Full Text] [Related]
17. Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis.
Ikuta T; Atweh G; Boosalis V; White GL; Da Fonseca S; Boosalis M; Faller DV; Perrine SP
Ann N Y Acad Sci; 1998 Jun; 850():87-99. PubMed ID: 9668531
[TBL] [Abstract][Full Text] [Related]
18. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
19. [Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin].
de Montalembert M
Pathol Biol (Paris); 1999 Jan; 47(1):55-8. PubMed ID: 10081780
[TBL] [Abstract][Full Text] [Related]
20. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
